X-linked severe combined immunodeficiency patient cell engraftment in human-sheep chimeras
| Donor cells . | Animal no. . | Human cells injected, no. . | Age at sampling (mo) . | Human cell chimerism, %4-150 . | Human myeloid cells, %4-151 . | Human lymphoid cells, % . | |
|---|---|---|---|---|---|---|---|
| T cells‡ . | B cells4-153 . | ||||||
| Pt 1, untransduced | 1457 | 4 × 105 | 3 | 3.1 | 55 | 0 | 0 |
| 1459 | 4 × 105 | 3 | 3.4 | 91 | 0 | 0 | |
| Pt 1, transduced | 1461 | 1.8 × 105 | 3 | 2.4 | 95 | 4 | 1 |
| 1465 | 1.8 × 105 | 3 | 5.1 | 79 | 18 | 3 | |
| 1466 | 1.8 × 105 | 3 | 4.8 | 79 | 15 | 6 | |
| 1467 | 1.8 × 105 | 3 | 2.0 | 47 | 43 | 10 | |
| 1468 | 1.8 × 105 | 3 | 4.0 | 69 | 22 | 9 | |
| Pt3, untransduced | 1506 | 2 × 106 | 1 | 1.4 | 93 | 0 | 0 |
| 10 | 3.6 | 88 | 0 | 0 | |||
| Pt 3, transduced | 1508 | 5 × 106 | 1 | 3.9 | 71 | 10 | 19 |
| 10 | 4.5 | 73 | 7 | 20 | |||
| Donor cells . | Animal no. . | Human cells injected, no. . | Age at sampling (mo) . | Human cell chimerism, %4-150 . | Human myeloid cells, %4-151 . | Human lymphoid cells, % . | |
|---|---|---|---|---|---|---|---|
| T cells‡ . | B cells4-153 . | ||||||
| Pt 1, untransduced | 1457 | 4 × 105 | 3 | 3.1 | 55 | 0 | 0 |
| 1459 | 4 × 105 | 3 | 3.4 | 91 | 0 | 0 | |
| Pt 1, transduced | 1461 | 1.8 × 105 | 3 | 2.4 | 95 | 4 | 1 |
| 1465 | 1.8 × 105 | 3 | 5.1 | 79 | 18 | 3 | |
| 1466 | 1.8 × 105 | 3 | 4.8 | 79 | 15 | 6 | |
| 1467 | 1.8 × 105 | 3 | 2.0 | 47 | 43 | 10 | |
| 1468 | 1.8 × 105 | 3 | 4.0 | 69 | 22 | 9 | |
| Pt3, untransduced | 1506 | 2 × 106 | 1 | 1.4 | 93 | 0 | 0 |
| 10 | 3.6 | 88 | 0 | 0 | |||
| Pt 3, transduced | 1508 | 5 × 106 | 1 | 3.9 | 71 | 10 | 19 |
| 10 | 4.5 | 73 | 7 | 20 | |||
Peripheral blood from sheep chimeras was analyzed by staining with antibodies specific for human cells (anti-CD45), human T cells (anti-CD3), human B cells (anti-CD19), and human myeloid cells (anti-CD11b), as well as human γc (TUGh4 anti-γc). Pt 1 was a γ XSCID patient. Pt 3 was a γ XSCID patient whose cells expressed truncated γc.
Percentage of human-specific CD45+ cells.
Percentage of double-positive CD11b+CD15+ and single-positive CD11b+, CD15+; or CD3−CD19/20− of CD45+ cells.
Percentage of CD3+CD19/20− of CD45+ cells. An entry of 0 indicates the percentage of detected cells not different from CD45− cells.
Percentage of CD19/20+CD3− of CD45+ cells. An entry of 0 indicates the percentage of detected cells not different from CD45− cells.